StimCardio Medical

Cover Block

From the public record

Field	Value
Name	StimCardio Medical
Tagline	Developing non-invasive, wearable neuromodulation for cardiovascular disorders, initially atrial fibrillation.
Headquarters	Los Angeles, United States
Founded	2016
Stage	Series A
Business Model	Hardware + Software
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Series A
Total Disclosed Funding	~$30,000,000 [BioSpace/PR Newswire, October 2026]

Links

From the public record

• Website: https://www.stimcardio.com/

The Short Version

PUBLIC StimCardio Medical is a clinical-stage medtech company developing a wrist-worn neuromodulation therapy for atrial fibrillation, and it warrants investor attention now because it has announced a $30 million Series A to fund a pivotal study and FDA De Novo preparation for its lead device [BioSpace/PR Newswire, October 2026] [Finsmes, October 2026]. Founded in 2016 and previously known as CardiaCare, the company is pursuing a specific wedge inside post-ablation AF care rather than a broad consumer wearable strategy, using non-invasive median nerve stimulation as the therapeutic mechanism [Crunchbase] [Life Science Intelligence] [Neurofounders]. Its lead product, Rhyvive, is described as an investigational wrist-worn device that combines physiological sensing with personalized, closed-loop neuromodulation, with positioning as an adjunct to catheter ablation intended to reduce recurrent atrial arrhythmias after the procedure [BioSpace/PR Newswire, October 2026] [StimCardio].

The team appears technically and clinically oriented in the public record: StimCardio identifies Amos Ziv as founder and chief scientific officer, while company materials and trade coverage identify Amir Soltanianzadeh as CEO [StimCardio] [StimCardio, April 2025] [Finsmes, October 2026]. Public materials also tie Metis Medtech founder John Slump to the board, which matters because Metis led the Series A and suggests close investor involvement beyond passive capital [StimCardio] [BioSpace/PR Newswire, October 2026]. The disclosed business model is best read as hardware plus software, with the product framed around at-home disease management and clinical use in the post-ablation pathway rather than a standalone wellness device [StimCardio] [StimCardio careers].

The near-term question is less about category interest than evidence depth. Management and financing materials point to a NeuroPulse 2 pivotal study and De Novo preparation, while public references to earlier NeuroPulse and first-in-human work remain only partially corroborated outside company channels [BioSpace/PR Newswire, October 2026] [Morningstar] [Yahoo Finance]. Investors should also note a small but real disclosure inconsistency: the company overview references a "$25M Series A Financing," while the October 2026 financing announcement states $30 million, which does not invalidate the round but does put a premium on document-level diligence [StimCardio] [BioSpace/PR Newswire, October 2026]. Over the next 12 to 18 months, the key watchpoints are pivotal-study execution, the quality of peer-reviewed clinical evidence, and whether StimCardio can translate an interesting mechanism into a regulatorily credible, reimbursable AF care product [BioSpace/PR Newswire, October 2026] [Guided Solutions, October 2026].

Unconfirmed -- This section relies materially on company materials and a financing announcement, with partial corroboration from trade coverage and profile sources.

Taxonomy Snapshot

Axis	Value
Stage	Series A
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Series A, total disclosed approximately $30,000,000

The Company in Brief

PUBLIC

StimCardio Medical presents as a clinical-stage medtech company built around a specific thesis, that atrial fibrillation care may be extended beyond the procedure room through a wearable neuromodulation system rather than another implant or monitoring-only product [StimCardio] [Crunchbase]. Public company materials identify Los Angeles as headquarters and 2016 as the founding year, while Crunchbase also lists the business under its current name StimCardio Medical and notes its former identity as CardiaCare [StimCardio] [Crunchbase].

The founding team publicly tied to that transition is compact. StimCardio names Amos Ziv as founder and chief scientific officer on its company overview page, and company materials from April 2025 identify Amir Soltanianzadeh as CEO in coverage connected to the earlier CardiaCare identity [StimCardio] [StimCardio, April 2025]. Crunchbase separately associates Soltanianzadeh with StimCardio Medical and records the company as venture-backed at the Series A stage [Crunchbase].

The visible milestone path is still thin, but the chronology is reasonably clear from public records. The company was founded in 2016, later operated publicly as CardiaCare, and by 2025 was still using that earlier name in external materials tied to LSI coverage before appearing as StimCardio Medical in 2026 financing and corporate materials [Crunchbase] [StimCardio, April 2025] [StimCardio]. That rebrand matters because investors should read older clinical and company references under both names when tracing the development record.

Single-source, plausible -- Company identity, headquarters, founding year, and name history are supported by StimCardio and Crunchbase, but founder-role details rely primarily on company materials.

What They Have Built

MIXED

StimCardio is building around a narrower claim than many cardiac-device startups make in early materials. Its lead product, Rhyvive, is described as an investigational wrist-worn therapeutic for atrial fibrillation that combines physiological sensing with personalized median nerve stimulation in a closed-loop system, with the initial use case positioned as an adjunct to catheter ablation rather than a replacement for it [BioSpace/PR Newswire, October 2026] [StimCardio] [Life Science Intelligence]. That positioning matters because it places the device inside a defined post-ablation workflow, at least in public materials, instead of stretching toward a general wellness or broad remote-monitoring story [BioSpace/PR Newswire, October 2026] [StimCardio].

The technical description remains directionally clear but still sparse in the public record. StimCardio says the platform integrates continuous physiological sensing with personalized therapy, and the careers page describes a non-invasive AF therapy that combines advanced cardiac monitoring with proprietary neurostimulation in a closed-loop wearable [StimCardio] [StimCardio careers]. Public claims on clinical performance are also early-stage and unevenly sourced: the company has said its NeuroPulse study showed a substantial reduction in recurrent AF events after ablation, while trade coverage and company-linked posts state that NeuroPulse pilot data was presented at HRX Live 2026 and published in Heart Rhythm [StimCardio] [Yahoo Finance] [Morningstar]. The underlying study design, sample size, and endpoint definitions are not fully established in the available public sources, so any read on efficacy should remain provisional.

The announced development path is more concrete than the rest of the product disclosure. StimCardio said in its October 2026 financing announcement that Series A proceeds are intended to support the NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission, which suggests the company is still in the clinical and regulatory buildout phase rather than near broad commercialization [BioSpace/PR Newswire, October 2026] [Finsmes, October 2026]. The same materials and website history indicate continuity from the earlier CardiaCare identity to the current StimCardio brand, with the core concept centered on closed-loop neuromodulation for AF management [Crunchbase] [Life Science Intelligence] [StimCardio, April 2025].

Single-source, plausible -- Product positioning is corroborated across company materials, trade coverage, and an industry interview, but several technical and clinical claims remain company-led or only partially corroborated in public sources.

Market Size and Demand

PUBLIC The market matters now because atrial fibrillation care is already large, procedure-heavy, and recurrence-sensitive, which creates room for therapies that sit between episodic intervention and home-based follow-up, even when the exact addressable market for StimCardio itself is not yet publicly sized [BioSpace/PR Newswire, October 2026] [StimCardio, Unknown].

The public record here is narrower than investors might like. StimCardio has described Rhyvive as an investigational, wrist-worn therapy intended as an adjunct to catheter ablation for reducing recurrent atrial arrhythmias after the procedure, and the October 2026 financing announcement says fresh capital will support a NeuroPulse 2 pivotal study and FDA De Novo preparation [BioSpace/PR Newswire, October 2026]. That gives a clear clinical wedge, post-ablation atrial fibrillation management, but not a company-specific TAM, SAM, or SOM from a named third-party market study. In that absence, the most defensible market reading is qualitative: this is not a general wellness wearable play, but a focused medtech attempt to capture part of the AF treatment pathway through a prescribed, investigational device tied to cardiology care [BioSpace/PR Newswire, October 2026] [Life Science Intelligence].

Demand drivers are visible even without hard market-sizing data in the source set. First, StimCardio is targeting recurrence after ablation, which matters because ablation is not framed by the company as curative in every case; its own positioning assumes a need for additional management once patients return home [BioSpace/PR Newswire, October 2026] [StimCardio, Unknown]. Second, the product concept combines continuous physiological sensing with therapy delivery, which aligns with a broader shift in cardiology toward longitudinal monitoring rather than one-time intervention, though the evidence here remains company-led rather than independently benchmarked [StimCardio, Unknown] [StimCardio careers, Unknown]. Third, the company is explicitly pursuing a non-invasive modality, median nerve stimulation, which if validated could fit physician and patient interest in lower-burden adjunctive therapies before escalating to more invasive repeat treatment [BioSpace/PR Newswire, October 2026] [Neurofounders].

The adjacent and substitute markets are easier to identify than the market size. The nearest adjacency is cardiac rhythm monitoring, because StimCardio repeatedly describes a platform that integrates physiological sensing with therapy [StimCardio, Unknown] [StimCardio careers, Unknown]. The more direct substitute is conventional post-ablation management without a wearable neuromodulation layer, including standard follow-up and any repeat interventional care implied by recurrent arrhythmia, although the sources do not enumerate competing care pathways in detail [BioSpace/PR Newswire, October 2026]. There is also a category overlap with implantable or procedural neuromodulation concepts in broader medtech, but StimCardio's differentiation, based on public materials, rests on being non-invasive and wrist-worn rather than on replacing ablation itself [Neurofounders] [BioSpace/PR Newswire, October 2026].

Regulatory and macro forces cut both ways. On the positive side, the company has named an FDA De Novo path and a planned pivotal study, which suggests a route to market that is legible to investors and strategic partners if clinical endpoints hold up [BioSpace/PR Newswire, October 2026]. The constraint is that this remains an investigational device, and the available public evidence does not yet provide the sort of third-party reimbursement, utilization, or guideline support that would turn clinical interest into a clearly underwritten commercial market [BioSpace/PR Newswire, October 2026] [StimCardio, Unknown]. That keeps the market discussion anchored less in current revenue pools and more in a conditional bet: if post-ablation recurrence reduction can be shown consistently in peer-reviewed and pivotal settings, the company could be selling into an established care pathway rather than trying to create a consumer habit from scratch [Morningstar] [Yahoo Finance].

Market lens	Publicly supported read	Source
Core entry point	Post-ablation atrial fibrillation management with a wearable adjunctive therapy	[BioSpace/PR Newswire, October 2026]
Delivery model	At-home, wrist-worn, non-invasive neuromodulation with sensing	[BioSpace/PR Newswire, October 2026] [StimCardio, Unknown]
Adjacent category	Cardiac monitoring and longitudinal rhythm management	[StimCardio, Unknown] [StimCardio careers, Unknown]
Regulatory framing	Planned pivotal study and FDA De Novo preparation	[BioSpace/PR Newswire, October 2026]

The table shows a market story defined more by care-pathway position than by published dollar sizing. For now, the investable question is whether StimCardio can convert a clinically specific use case into a reimbursable device category, not whether atrial fibrillation itself is a meaningful disease area.

Single-source, plausible -- This section relies on one independent trade publication for the financing, regulatory path, and product positioning, with partial corroboration from company materials and secondary coverage [BioSpace/PR Newswire, October 2026] [StimCardio, Unknown] [Finsmes, October 2026].

Who Else Is Fighting for This

Competitive set

MIXED StimCardio is not competing for general wellness wearable share, it is trying to carve out a narrower lane at the intersection of post-ablation atrial fibrillation care, neuromodulation, and investigational home-based therapy, with Rivia the only named direct startup comparator in the available public record [BioSpace/PR Newswire, October 2026] [StimCardio, Unknown].

Company	Positioning	Stage / Funding	Notable Differentiator	Source
StimCardio Medical	Developing an investigational wrist-worn therapeutic for atrial fibrillation, positioned as an adjunct to catheter ablation	Series A, $30 million announced in October 2026	Closed-loop integration of physiological sensing with personalized median nerve stimulation in a wrist-worn format	[BioSpace/PR Newswire, October 2026] [StimCardio, Unknown]
Rivia	Named competitor in the structured research	Public sources provided here do not confirm stage or funding	Competitive relevance is established in the source set, but the available materials here do not substantiate a more specific product comparison	[Structured facts]

The competitive map breaks into three layers. Incumbents sit in the atrial fibrillation care pathway itself, led by catheter ablation and the electrophysiology workflow that surrounds it, because StimCardio explicitly positions Rhyvive as an adjunct rather than a replacement [BioSpace/PR Newswire, October 2026]. Adjacent substitutes include standard post-procedure monitoring and broader patient management tools, which can compete for clinician attention and budget even if they do not offer the same therapeutic mechanism [StimCardio, Unknown].

StimCardio's edge, such as it can be assessed from public evidence, is conceptual fit with an existing care episode rather than a proven distribution advantage. The company is targeting a defined point of clinical vulnerability, recurrent atrial arrhythmia after ablation, and pairing that with a non-invasive form factor that is easier to picture in home use than an implant-based approach [BioSpace/PR Newswire, October 2026] [Life Science Intelligence]. That edge is still perishable. The public record does not yet show commercial provider contracts, reimbursement coverage, or named health-system deployments, so the present advantage rests more on product thesis and clinical-development progress than on locked-in channel control [StimCardio, Unknown].

The main exposure is that StimCardio does not appear to own the primary treatment channel. Because the company frames Rhyvive as an adjunct to ablation, electrophysiologists and ablation-centered care pathways remain the gatekeepers, which leaves room for incumbents and other post-procedure solutions to shape adoption criteria before a startup wearable does [BioSpace/PR Newswire, October 2026]. A named rival such as Rivia could matter if it reaches stronger clinical validation, payer traction, or physician workflow integration first, and established monitoring vendors could also absorb attention if clinicians decide that better detection, not adjunctive neuromodulation, is the more urgent unmet need. Public materials also leave a credibility wrinkle: StimCardio's About page references a "$25M Series A Financing," while the October 2026 financing announcement states $30 million, a small discrepancy that does not change the category position but does warrant diligence on capital history [StimCardio, Unknown] [BioSpace/PR Newswire, October 2026].

Over the next 18 months, the most plausible competitive outcome is that the field is sorted less by branding than by clinical and regulatory proof. StimCardio is the likely winner if its planned NeuroPulse 2 pivotal study advances on schedule and translates the company's early neuromodulation narrative into evidence credible enough for FDA De Novo preparation, because that would move it from concept differentiation toward category definition [BioSpace/PR Newswire, October 2026] [StimCardio, Unknown]. Rivia is the likely winner if it reaches the same physician audience with stronger validation or an easier adoption path first. StimCardio is the likely loser if the category remains clinically interesting but operationally subordinate to incumbent ablation follow-up, in which case the company could end up as a feature in someone else's pathway rather than the platform owner.

Opportunity

PUBLIC

The prize here is not simply another atrial fibrillation device, but a chance to define a new post-ablation care layer in cardiology if non-invasive neuromodulation proves durable in pivotal data and wins a workable regulatory path [BioSpace/PR Newswire, October 2026] [StimCardio, Unknown].

The headline opportunity is straightforward. StimCardio is trying to turn a procedure-centric atrial fibrillation treatment pathway into an ongoing at-home therapy model built around an investigational wrist-worn device, Rhyvive, which the company positions as an adjunct to catheter ablation rather than a replacement for it [BioSpace/PR Newswire, October 2026]. That matters because the company is not asking electrophysiologists to abandon an established intervention. It is asking them to extend care after ablation using a modality that is non-invasive, wearable, and tied to continuous physiological sensing with personalized median nerve stimulation [BioSpace/PR Newswire, October 2026] [StimCardio, Unknown]. The outcome that would justify real venture-scale upside is a category-defining platform for post-ablation arrhythmia management, starting in AF and then broadening into adjacent cardiovascular disorders if the same sensing-plus-neuromodulation architecture holds up clinically [StimCardio, Unknown].

That outcome is still conditional, but not purely aspirational, because the public record shows more than a concept-stage story. The company has raised a $30 million Series A led by Metis Medtech, with participation from Catalyst Health Ventures and other investors, specifically to fund the planned NeuroPulse 2 pivotal study and FDA De Novo preparation [BioSpace/PR Newswire, October 2026] [Finsmes, October 2026] [Guided Solutions, October 2026]. Public materials also indicate that NeuroPulse pilot data was presented at HRX Live 2026 and published in Heart Rhythm, although the detailed endpoint package and sample size are not available in the present source set [Yahoo Finance] [Morningstar]. In medtech terms, that combination, investigational product definition, named financing, stated pivotal-study plan, and at least some public signal of peer-reviewed clinical visibility, is enough to treat the upside case as reachable if subsequent data confirms efficacy and usability.

The most plausible paths to scale are easier to see when broken into specific operating outcomes.

Scenario	What happens	Catalyst	Why it's plausible
Post-ablation standard adjunct	Rhyvive becomes a recognized adjunct therapy after AF ablation, giving electrophysiology programs a home-based tool to reduce recurrent atrial arrhythmias	Positive NeuroPulse 2 pivotal readout and progress toward FDA De Novo submission [BioSpace/PR Newswire, October 2026]	The company is already positioning the device for this exact use case, and the Series A is earmarked for the pivotal study and regulatory preparation [BioSpace/PR Newswire, October 2026] [Finsmes, October 2026]
Closed-loop cardiac neuromodulation platform	The initial AF indication validates a broader platform that applies continuous sensing plus personalized neuromodulation to additional cardiovascular disorders	Clinical proof that the closed-loop architecture works reproducibly in AF, followed by indication expansion [StimCardio, Unknown] [BioSpace/PR Newswire, October 2026]	Company materials consistently describe the platform, not just a single device, as integrating continuous physiological sensing with personalized therapy for cardiovascular disorders [StimCardio, Unknown]
Strategic medtech tuck-in	A larger cardiovascular or device company acquires StimCardio after pivotal-risk reduction to add a differentiated non-invasive therapy into its electrophysiology or remote-care portfolio	Peer-reviewed clinical validation plus a clearer De Novo timeline [BioSpace/PR Newswire, October 2026] [Morningstar]	The cap table already includes corporate strategic investors, according to the financing announcement, which at minimum suggests strategic visibility early in the company's life cycle [BioSpace/PR Newswire, October 2026]

The compounding logic, if this works, comes from fit with existing care pathways rather than from consumer-style virality. A wearable adjunct used after ablation can create a clinician adoption loop: better recurrence management supports physician confidence, physician confidence supports more prescribing and follow-up integration, and more usage should improve the company's understanding of which physiological signals best map to therapy personalization [BioSpace/PR Newswire, October 2026] [StimCardio, Unknown]. Because StimCardio describes the product as a closed-loop system combining sensing with neuromodulation, the economic and clinical value could improve together if additional real-world usage sharpens therapy protocols over time, subject to regulatory constraints on how such personalization is implemented [StimCardio, Unknown] [StimCardio careers, Unknown].

There is also an early distribution signal worth noticing. The company's single surfaced role is for a Senior Clinical Research Associate, which is a narrow data point, but directionally consistent with a business moving deeper into formal clinical execution rather than broad commercial hiring too early [StimCardio careers, Unknown]. In medtech, that sequencing can matter. If the pivotal program is successful, the installed base of physician relationships, publication record, and strategic investor network can all shorten the path from evidence generation to commercial discussions.

The size of the win is difficult to anchor tightly from the current public record because no market-sizing source or directly comparable public peer was provided in the source set. Even so, a reasonable upside frame is this: if StimCardio becomes the recognized post-ablation adjunct in AF, with a De Novo-cleared product and strategic relevance to larger electrophysiology players, the company could plausibly become an acquisition target for a cardiovascular-device incumbent or a scaled independent therapeutic platform in cardiac neuromodulation (scenario, not a forecast) [BioSpace/PR Newswire, October 2026] [Guided Solutions, October 2026]. The present evidence supports a real, if still highly execution-dependent, shot at defining a new treatment layer between the ablation lab and the patient's home.

Single-source, plausible -- This section relies on one independently reported financing event corroborated by multiple trade publications, plus substantial company-originated product and platform claims that are only partially corroborated by third-party references.

Sources

From the public record

1. [BioSpace/PR Newswire, October 2026] StimCardio Closes Oversubscribed $30 Million Series A Financing to Advance Wearable Therapeutic for Atrial Fibrillation | https://www.biospace.com/press-releases/stimcardio-closes-oversubscribed-30-million-series-a-financing-to-advance-wearable-therapeutic-for-atrial-fibrillation

2. [Finsmes, October 2026] StimCardio Raises $30M in Series A Funding | https://www.finsmes.com/2026/10/stimcardio-raises-30m-in-series-a-funding.html

3. [Crunchbase] StimCardio Medical (formerly CardiaCare) - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/stimcardio-medical

4. [Life Science Intelligence] Amos Ziv, CardiaCare - Studio Interview | LSI Europe ‘22 | https://www.lifesciencemarketresearch.com/videos/amos-ziv-cardia-care-studio-interview-lsi-europe-22

5. [Neurofounders] StimCardio - Developing a wrist-worn, closed-loop median nerve stimulation device that modulates autonomic balance to reduce atrial fibrillation recurrence. | https://www.neurofounders.co/startups/stimcardio

6. [StimCardio] StimCardio | Advanced Cardiac Stimulation Technology | https://www.stimcardio.com/

7. [StimCardio, April 2025] StimCardio | LSI Alumni Innovator Spotlight, CardiaCare CEO Amir Soltanianzadeh | https://www.stimcardio.com/news-articles/lsi-alumni-innovator-spotlight-cardiacare-ceo-amir-soltanianzadeh

8. [Morningstar, 2026] Non-Invasive Median Nerve Stimulation with a Wearable Stimulator to Reduce Atrial Arrhythmia Recurrence after Atrial Fibrillation Ablation: The NEUROPULSE Pilot | https://www.morningstar.com/news/globe-newswire/1001150957/non-invasive-median-nerve-stimulation-with-a-wearable-stimulator-to-reduce-atrial-arrhythmia-recurrence-after-atrial-fibrillation-ablation-the-neuropulse-pilot

9. [Yahoo Finance] StimCardio Medical Announces Positive NeuroPulse Pilot Trial Data in Late Breaking Clinical Science Presentation at HRX 2026 and Simultaneous Publication in Heart Rhythm | https://finance.yahoo.com/news/stimcardio-medical-announces-positive-neuropulse-120000000.html

10. [Guided Solutions, October 2026] StimCardio raises $30M Series A for wearable AF therapy | https://www.gsmedtech.com/insights/article/stimcardio-raises-30m-series-a-for-wearable-af-therapy

11. [StimCardio careers] Senior Clinical Research Associate (Senior CRA) | https://www.stimcardio.com/careers/senior-clinical-research-associate-senior-cra